Research Information System
Future Oncology, vol.22, no.4, pp.445-453, 2026 (SCI-Expanded, Scopus)
Background: The glucose-to-lymphocyte ratio (GLR) has recently gained attention as a composite biomarker reflecting systemic inflammation and metabolic dysregulation. While its prognostic value has been reported in various malignancies, its clinical utility in endometrial cancer remains unknown. This study aimed to evaluate the prognostic relevance of GLR in surgically treated patients with endometrial cancer. Methods: We retrospectively analyzed 165 patients who underwent total abdominal hysterectomy for endometrial cancer between January 2021 and January 2025. GLR was calculated by dividing fasting glucose levels by absolute lymphocyte count. Patients were classified into GLR-high and GLR-low groups using the median value (3.70). Disease-free survival (DFS) and overall survival (OS) were compared using Kaplan–Meier curves and Cox regression analysis. Results: The median follow-up was 17.4 months. High GLR was independently associated with shorter DFS (HR: 2.05; 95% CI: 1.08–3.89; p = 0.029). A trend toward shorter OS was also noted (HR: 2.29; p = 0.056). Additional factors linked to poorer survival included absence of adjuvant radiotherapy, high tumor grade, and advanced stage. Conclusion: GLR is an independent prognostic factor for DFS in endometrial cancer and may serve as a readily available, cost-effective biomarker. Further prospective studies are needed for validation.